HDAC9 and Miyoshi myopathy: While the pan-HDAC inhibitors vorinostat, belinostat, romidepsin, and panobinostat have been approved by the FDA for treatment of T-cell lymphoma or MM, their clinical utility is frequently limited due to poor tolerability, particularly in combination settings [24–27].